Disitamab vedotin, an anti-HER2 antibody–drug conjugate (ADC) carrying the microtubule inhibitor MMAE. It binds HER2 (ERBB2) on tumor cells, is internalized, and releases MMAE to disrupt microtubules and induce cell death; the antibody component may also mediate ADCC and a bystander effect.
Disitamab vedotin (RC48) is an anti-HER2 antibody–drug conjugate that binds HER2 (ERBB2) on tumor cells, is internalized, and releases the microtubule inhibitor MMAE. MMAE inhibits tubulin polymerization, leading to microtubule disruption, G2/M arrest, and apoptosis. The antibody component may also mediate ADCC and a bystander effect.
NO
INDIRECT
RC48 targets HER2 on the cell surface; after internalization it releases MMAE, which binds the vinca site on beta-tubulin to disrupt microtubules and induce G2/M arrest and apoptosis. Beta-tubulin itself is not the targeting antigen.
A human monoclonal antibody targeting HBsAg that neutralizes HBV virions/subviral particles and, via Fc engineering, enhances Fcγ receptor–mediated effector functions (ADCC/ADCP) to promote clearance of HBsAg-expressing hepatocytes.
Human monoclonal antibody to HBsAg that neutralizes circulating HBV virions and subviral particles and, via Fc engineering, enhances Fc gamma receptor–mediated effector functions (ADCC/ADCP) to promote clearance of HBsAg-expressing hepatocytes and reduce HBsAg levels.
YES
DIRECT
Fc-engineered anti-HBsAg antibody opsonizes HBsAg+ hepatocytes and engages Fcγ receptors on NK cells/macrophages to trigger ADCC/ADCP, leading to killing/clearance of target cells.
A human monoclonal antibody targeting HBsAg that neutralizes HBV virions/subviral particles and, via Fc engineering, enhances Fcγ receptor–mediated effector functions (ADCC/ADCP) to promote clearance of HBsAg-expressing hepatocytes.
Human monoclonal antibody to HBsAg that neutralizes circulating HBV virions and subviral particles and, via Fc engineering, enhances Fc gamma receptor–mediated effector functions (ADCC/ADCP) to promote clearance of HBsAg-expressing hepatocytes and reduce HBsAg levels.
NO
INDIRECT
The antibody binds HBsAg on infected hepatocytes and uses its Fc to engage Fcγ receptors on NK cells/macrophages, triggering ADCC/ADCP that kills HBsAg+ hepatocytes; FcγR-expressing cells are not targeted for killing.
An antibody–drug conjugate targeting CEACAM5; after binding and internalization it releases the maytansinoid payload DM4 (ravtansine), a microtubule inhibitor that induces mitotic arrest and tumor cell death.
Monoclonal antibody targets CEACAM5 on tumor cells; after binding and internalization, the linker is cleaved to release the DM4 (ravtansine) maytansinoid payload, a microtubule inhibitor, causing mitotic arrest and tumor cell death.
YES
DIRECT
ADC binds CEACAM5, is internalized, and releases the DM4 (ravtansine) microtubule inhibitor, causing mitotic arrest and apoptosis of the target-expressing cells.
An antibody–drug conjugate targeting CEACAM5; after binding and internalization it releases the maytansinoid payload DM4 (ravtansine), a microtubule inhibitor that induces mitotic arrest and tumor cell death.
Monoclonal antibody targets CEACAM5 on tumor cells; after binding and internalization, the linker is cleaved to release the DM4 (ravtansine) maytansinoid payload, a microtubule inhibitor, causing mitotic arrest and tumor cell death.
NO
INDIRECT
Tusamitamab ravtansine binds CEACAM5 on tumor cells, is internalized, and releases the DM4 payload that binds beta‑tubulin to disrupt microtubules and cause mitotic arrest; cells are not killed based on beta‑tubulin expression alone.